Aberrant Expression of Citrate Synthase is Linked to Disease Progression and Clinical Outcome in Prostate Cancer
Authors:
Open Access
- 1 July 2020
- journal article
- research article
- Published by Taylor & Francis in Cancer Management and Research
- Vol. ume 12, 6149-6163
Abstract
Purpose: Citrate synthase (CS) is a rate-limiting enzyme in the citrate cycle and is capable of catalyzing oxaloacetate and acetyl-CoA to citrate. CS has been uncovered to be upregulated in a variety of cancers, and its expression and clinical significance in prostate cancer (PCa) remain unknown. Methods: In this study, we examined the association between CS expression level and clinicopathological features of prostate cancer patients in a TMA cohort and the public cancer database (The Cancer Genome Atlas-Prostate Adenocarcinoma, TCGA-PRAD). The CS knockdown cell lines were constructed to study the effects of CS downregulation on proliferation, colony formation, migration, invasion, and cell cycle of prostate cancer cells in vitro. And the effect of CS downregulation on tumor growth in mice was studied in vivo. In addition, the metabolomics and mitochondrial function were detected in the CS knockdown cell lines. Results: CS expression level in PCa tissues was higher than that in normal tissues (P < 0.05). CS upregulation was significantly associated with high Gleason score (P < 0.05), advanced pathological stage (P < 0.001), and biochemical recurrence (P < 0.001). Functionally, decreased expression of CS inhibited PCa cell proliferation, colony formation, migration, invasion and cell cycle in vitro, and inhibited tumor growth in vivo. In addition, CS downregulation exerted potential inhibitory effects on the lipid metabolism and mitochondrial function of PCa cells. Conclusion: In conclusion, these findings suggested that CS upregulation may contribute to the aggressive progression and poor prognosis of PCa patients, which might be partially associated with its influences on the cell lipid metabolism and mitochondrial function.Keywords
This publication has 32 references indexed in Scilit:
- α-Methylacyl-CoA racemase (AMACR): Metabolic enzyme, drug metabolizer and cancer marker P504SProgress in Lipid Research, 2013
- Loss of the respiratory enzyme citrate synthase directly links the Warburg effect to tumor malignancyScientific Reports, 2012
- The Correlation Between Metabolic Syndrome and Prostatic DiseasesEuropean Urology, 2012
- TCA Cycle Defects and Cancer: When Metabolism Tunes Redox StateInternational Journal of Cell Biology, 2012
- Mitochondria in cancer: Not just innocent bystandersSeminars in Cancer Biology, 2009
- Metabolomic profiles delineate potential role for sarcosine in prostate cancer progressionNature, 2009
- Liver-specific deletion of acetyl-CoA carboxylase 1 reduces hepatic triglyceride accumulation without affecting glucose homeostasisProceedings of the National Academy of Sciences, 2006
- Citrate enhances in vitro metastatic behaviours of PC-3M human prostate cancer cells: Status of endogenous citrate and dependence on aconitase and fatty acid synthaseThe International Journal of Biochemistry & Cell Biology, 2006
- Structure and regulation of acetyl-CoA carboxylase genes of metazoaBiochimica et Biophysica Acta (BBA) - Molecular and Cell Biology of Lipids, 2005
- Role of zinc in the pathogenesis and treatment of prostate cancer: critical issues to resolveProstate Cancer and Prostatic Diseases, 2004